Benign prostatic hyperplasia.
Conditions
Interventions
Intervention 1: Intervention group: In the intervention group, the main drug empagliflozin is prescribed at a dose of 25 mg daily for 3 months along with metformin at a dose of 500 to 2000 mg daily fo
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: Male patients above ?? years old, with evidence of type ? diabetes (fasting blood sugar = ??? mg/dL, HbA?c = ?.?%, or ?-hour post-prandial blood glucose = ??? mg/dL) and sonographic evidence of benign prostatic hyperplasia Evidence of lower urinary tract symptoms (IPSS Score moderate) Sonographic evidence of benign prostatic hyperplasia
Exclusion criteria
Exclusion criteria: Patients younger than ?? years old Having type ? diabetes mellitus Need for insulin use (HbA?c= ??.?%, weight loss, or fasting blood glucose = ??? mg/dL) Having the need for SGLT?i therapy for other reasons such as diabetic nephropathy or congestive heart failure, history of chronic kidney disease or hepatic impairment IPSS score: "severe" (due to need for other medications or surgery) Unwillingness to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lower urinary tract symptoms. Timepoint: At the beginning of the study, three months after taking the drug. Method of measurement: IPSS Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Peak urinary flow rate. Timepoint: At the beginning of the study and 3 months later. Method of measurement: Uroflowmetry.;Post void residual. Timepoint: At the beginning of the study and 3 months later. Method of measurement: KUB ultrasound.;PSA. Timepoint: At the beginning of the study and 3 months later. Method of measurement: blood sample study. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactArman Hosseini
Shiraz University of Medical Sciences
Outcome results
None listed